GlobalData on MSN4 天
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...
Pharmabiz5 天
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple ...
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation ...
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
治疗多系统萎缩的潜在药物 Amlenetug 获 FDA 快速通道认证
FDA 已授予 Lundbeck 的试验药物 amlenetug 快速通道资格，以进一步审查其作为多系统萎缩 (MSA) 患者的潜在新疗法的可能性。Amlenetug 旨在与细胞外 α-突触核蛋白的主要形式结合，从而阻止其吸收并抑制聚集。
abc271 个月
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track ...
The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
Morningstar6 天
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation ...
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...
H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan ...
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...